Tanke Biosciences Corporation

Total Valuation

Tanke Biosciences Corporation carries a market capitalization of 422,498.00, placing it among publicly traded companies globally. Its enterprise value stands at 7.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Tanke Biosciences Corporation currently has 13.32M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.12, and the price-to-book ratio stands at 1.63.

Enterprise Valuation

On an enterprise value basis, Tanke Biosciences Corporation trades at an EV/EBITDA multiple of 8.84 and an EV/FCF ratio of 4.28. The EV/Sales ratio of 0.31 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.31 provides insight into valuation relative to core operating earnings.

Financial Position

Tanke Biosciences Corporation maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.71, indicating elevated leverage, while an interest coverage ratio of 1.25 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Tanke Biosciences Corporation has paid 237,590.00 in income taxes, reflecting an effective tax rate of 31.63.

Stock Price Statistics

Tanke Biosciences Corporation's stock has declined approximately -50% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.04.

Income Statement

Over the trailing twelve months, Tanke Biosciences Corporation generated 22.96M in revenue and converted that into -1.64M in net income, yielding earnings per share of -0.13. EBITDA reached 804,294.00, while operating income came in at -57,268.00.

Balance Sheet

Tanke Biosciences Corporation holds 5.09M in cash and equivalents against 9.38M in total debt, resulting in a net debt position of 4.29M. Total book value stands at 1.64M, with working capital of 7.46M providing operational flexibility.

Cash Flow

Tanke Biosciences Corporation produced -3.78M in operating cash flow over the past twelve months. After subtracting -2.53M in capital expenditures, free cash flow totaled -6.31M - equivalent to -0.47 per share.

Margins

Tanke Biosciences Corporation operates with a gross margin of 32.28, reflecting its pricing power and cost economics. The operating margin of -0.25 and net profit margin of -7.15 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Tanke Biosciences Corporation's most recent stock split took place on June 7, 2011 with a 1000:117 split ratio.

Scores

Tanke Biosciences Corporation posts an Altman Z-Score of 1.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.